Taysha Gene Therapies and Acadia Pharmaceuticals present positive clinical data and real-world evidence, respectively, for Rett Syndrome. Neurogene announces dosing of the first patient in a high-dose cohort for gene therapy in Rett Syndrome.
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting https://t.co/L1d3ukltJa #news #biotech
Taysha Gene Therapies has unfurled more data in the developmental disorder Rett syndrome, linking its gene therapy to improvements in the first adults and children to receive low doses of the candidate. $TSHA https://t.co/1hVEBdr80q
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome https://t.co/GMudhSO9Am https://t.co/JLask0NhXo
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome $NGNE https://t.co/DgA9q4wtgH
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting $ACAD https://t.co/BJVl4Fgx2S
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome $TSHA https://t.co/sRusZ1qMqZ